CN104755096B - 重构的hdl配制剂 - Google Patents

重构的hdl配制剂 Download PDF

Info

Publication number
CN104755096B
CN104755096B CN201380057007.0A CN201380057007A CN104755096B CN 104755096 B CN104755096 B CN 104755096B CN 201380057007 A CN201380057007 A CN 201380057007A CN 104755096 B CN104755096 B CN 104755096B
Authority
CN
China
Prior art keywords
rhdl
preparatons
apolipoprotein
sucrose
lipid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380057007.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN104755096A (zh
Inventor
Y·武契察
G·L·沃伦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSL Ltd
Original Assignee
CSL Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CSL Ltd filed Critical CSL Ltd
Priority to CN201711141045.0A priority Critical patent/CN108057023B/zh
Publication of CN104755096A publication Critical patent/CN104755096A/zh
Application granted granted Critical
Publication of CN104755096B publication Critical patent/CN104755096B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201380057007.0A 2012-11-02 2013-10-31 重构的hdl配制剂 Active CN104755096B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201711141045.0A CN108057023B (zh) 2012-11-02 2013-10-31 重构的hdl配制剂

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201261721771P 2012-11-02 2012-11-02
US61/721,771 2012-11-02
EP13153903 2013-02-04
EP13153903.3 2013-02-04
US13/803,863 2013-03-14
US13/803,863 US9125943B2 (en) 2012-11-02 2013-03-14 Reconstituted HDL formulation
AU2013205684A AU2013205684B2 (en) 2012-11-02 2013-04-10 Reconstituted hdl formulation
AU2013205684 2013-04-10
PCT/AU2013/001260 WO2014066943A1 (en) 2012-11-02 2013-10-31 Reconstituted hdl formulation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201711141045.0A Division CN108057023B (zh) 2012-11-02 2013-10-31 重构的hdl配制剂

Publications (2)

Publication Number Publication Date
CN104755096A CN104755096A (zh) 2015-07-01
CN104755096B true CN104755096B (zh) 2017-10-13

Family

ID=47665977

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380057007.0A Active CN104755096B (zh) 2012-11-02 2013-10-31 重构的hdl配制剂
CN201711141045.0A Active CN108057023B (zh) 2012-11-02 2013-10-31 重构的hdl配制剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201711141045.0A Active CN108057023B (zh) 2012-11-02 2013-10-31 重构的hdl配制剂

Country Status (15)

Country Link
US (6) US9125943B2 (enExample)
EP (2) EP2916857B1 (enExample)
JP (1) JP6340372B2 (enExample)
KR (1) KR102263810B1 (enExample)
CN (2) CN104755096B (enExample)
AU (1) AU2013205684B2 (enExample)
BR (1) BR112015009748B1 (enExample)
CA (1) CA2889785C (enExample)
IL (1) IL238504B (enExample)
MX (1) MX364587B (enExample)
NZ (1) NZ631131A (enExample)
PL (1) PL2916857T3 (enExample)
RU (1) RU2669568C2 (enExample)
SG (1) SG11201503083UA (enExample)
WO (1) WO2014066943A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3178481T3 (en) 2010-06-30 2019-04-08 Csl Ltd FORMULATION WITH RECONSTITUTED HIGH DENSITY LIPOPROTEIN AND PROCEDURE FOR PREPARING THEREOF
US9125943B2 (en) * 2012-11-02 2015-09-08 Csl Limited Reconstituted HDL formulation
DK3004160T3 (da) 2013-06-05 2023-01-23 Csl Ltd Fremgangsmåde til fremstilling af apolipoprotein a-i (apo a-i)
AU2014305646C1 (en) 2013-08-08 2019-01-17 Csl Limited Contaminant removal method
WO2018019911A1 (en) 2016-07-27 2018-02-01 Hartis-Pharma Sarl Therapeutic combinations to treat red blood cell disorders
IL266428B2 (en) * 2016-11-10 2024-12-01 Csl Ltd High-density lipoprotein (HDL) is restored to treat myocardial infarction
CN112546201A (zh) * 2019-09-26 2021-03-26 中国科学院生物物理研究所 人工脂蛋白颗粒apoA-Ⅳ脂肪体在治疗和/或预防糖尿病中的应用
WO2025185021A1 (zh) * 2024-03-05 2025-09-12 维康平生(北京)生物科技有限公司 一种脂肪体的冷冻干燥方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007098122A2 (en) * 2006-02-17 2007-08-30 Pfizer, Inc. Methods for the treatment of macular degeneration and related eye conditions
WO2012000048A1 (en) * 2010-06-30 2012-01-05 Csl Limited A reconstituted high density lipoprotein formulation and production method thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1335077C (en) * 1988-02-08 1995-04-04 Henri Isliker Process for the manufacture of apolipoproteins from human blood plasma or serum
US5652339A (en) 1993-12-31 1997-07-29 Rotkreuzstiftung Zentrallaboratorium Method of producing reconstituted lipoproteins
MXPA04002848A (es) 2001-09-28 2005-06-06 Esperion Therapeutics Inc Prevencion y tratamiento de restenosis por administracion local de medicamento.
US20040067873A1 (en) 2002-05-17 2004-04-08 Dasseux Jean-Louis H. Method of treating dyslipidemic disorders
NZ537006A (en) 2002-05-17 2008-01-31 Esperion Therapeutics Inc The use of apolipoprotein A-I Milano, for the manufacture ofa composition for treating preventing or reducing ischemic reperfusion injury in a tissue or organ
PE20050438A1 (es) 2003-10-20 2005-06-14 Esperion Therapeutics Inc Formulas farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y la prevencion de sindromes coronarios agudos
KR100992488B1 (ko) 2006-12-29 2010-11-05 주식회사 녹십자 ＡｐｏＡ-Ｉ의 정제방법 및 정제된ＡｐｏＡ-Ｉ을 이용한재구축 ＨＤＬ의 생산 방법
WO2009025754A2 (en) 2007-08-17 2009-02-26 Csl Behring Gmbh Methods for purification of alpha-1-antitrypsin and apolipoprotein a-i
WO2010057203A2 (en) 2008-11-17 2010-05-20 The Board Of Regents Of The University Of Texas System Hdl particles for delivery of nucleic acids
PT2673296T (pt) * 2011-02-07 2019-01-31 Cerenis Therapeutics Holding Sa Complexos de lipoproteínas e sua fabricação e utilização
US9125943B2 (en) 2012-11-02 2015-09-08 Csl Limited Reconstituted HDL formulation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007098122A2 (en) * 2006-02-17 2007-08-30 Pfizer, Inc. Methods for the treatment of macular degeneration and related eye conditions
WO2012000048A1 (en) * 2010-06-30 2012-01-05 Csl Limited A reconstituted high density lipoprotein formulation and production method thereof

Also Published As

Publication number Publication date
KR102263810B1 (ko) 2021-06-15
IL238504A0 (en) 2015-06-30
WO2014066943A1 (en) 2014-05-08
US11957731B2 (en) 2024-04-16
US9925236B2 (en) 2018-03-27
EP3502131A1 (en) 2019-06-26
BR112015009748B1 (pt) 2021-04-27
US20150306176A1 (en) 2015-10-29
BR112015009748A2 (pt) 2017-07-11
US20200397859A1 (en) 2020-12-24
JP6340372B2 (ja) 2018-06-06
US20190015476A1 (en) 2019-01-17
US10603355B2 (en) 2020-03-31
MX2015004546A (es) 2015-07-14
CN108057023A (zh) 2018-05-22
CA2889785A1 (en) 2014-05-08
PL2916857T3 (pl) 2019-06-28
EP2916857A1 (en) 2015-09-16
CN104755096A (zh) 2015-07-01
US20230142696A1 (en) 2023-05-11
SG11201503083UA (en) 2015-05-28
CA2889785C (en) 2022-07-19
AU2013205684B2 (en) 2015-08-20
IL238504B (en) 2018-02-28
AU2013205684A1 (en) 2014-05-22
MX364587B (es) 2019-05-02
EP2916857A4 (en) 2016-05-25
RU2669568C2 (ru) 2018-10-12
US9125943B2 (en) 2015-09-08
CN108057023B (zh) 2022-02-08
NZ631131A (en) 2015-12-24
RU2015120808A (ru) 2016-12-20
EP2916857B1 (en) 2019-01-16
US11464828B2 (en) 2022-10-11
US20140221272A1 (en) 2014-08-07
JP2015535263A (ja) 2015-12-10
KR20150079947A (ko) 2015-07-08
HK1212599A1 (en) 2016-06-17
US20250099537A1 (en) 2025-03-27

Similar Documents

Publication Publication Date Title
US11957731B2 (en) Reconstituted HDL formulation
AU2011274238B2 (en) A reconstituted high density lipoprotein formulation and production method thereof
JP6174995B2 (ja) コレステリルエステルのステロイド産生組織への送達
KR102766038B1 (ko) 아포지질단백질 제형을 위한 용량 용법
WO2007096745A1 (en) Methods for the treatment of macular degeneration and related eye conditions
DK2916857T3 (en) RECONSTITUTED HDL FORMULATION
HK40010383A (en) Reconstituted hdl formulation
HK1212599B (en) Reconstituted hdl formulation
RU2776110C2 (ru) Схема дозирования для составов аполипопротеина
HK1199813B (en) Dosage regime for apolipoprotein formulations
NZ624558B2 (en) Dosage regime for apolipoprotein formulations

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: Vitoria Australia

Applicant after: Ztel company limited

Address before: Vitoria Australia

Applicant before: CSL Limited

COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; FROM:

Free format text: CORRECT: APPLICANT; FROM: CSL LIMITED TO: JETT LTD.

C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant